^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    AJUBA overexpression

    i
    Other names: AJUBA, Ajuba LIM Protein, LIM Domain-Containing Protein Ajuba, JUB, Jub Ajuba Homolog (Xenopus Laevis), Jub Ajuba Homolog, MGC15563
    Entrez ID:
    84962
    1year
    LIM domain-containing protein Ajuba inhibits chemotherapy-induced apoptosis by negatively regulating p53 stability in colorectal cancer cells. (PubMed, Mol Oncol)
    Therefore, Ajuba formed a negative feedback loop to regulate p53 expression and activity. In conclusion, as a novel p53 negative regulator, Ajuba inhibits the apoptosis of CRC cells induced by chemotherapeutic drugs and it may be a new therapeutic target for CRC treatment.
    Journal
    |
    TP53 (Tumor protein P53) • AJUBA (Ajuba LIM Protein)
    |
    AJUBA overexpression
    2years
    Ajuba Overexpression Promotes Breast Cancer Chemoresistance and Glucose Uptake through TAZ-GLUT3/Survivin Pathway. (PubMed, Biomed Res Int)
    Ectopically expressed Ajuba in MCF-7 cells stimulated in vitro and in vivo cell growth, invasion, cell cycle progression, and decreased paclitaxel-induced apoptosis...The ChIP assay showed that TEAD4, a major TAZ binding transcription factor, could bind to the GLUT3 and Survivin promoter regions. In conclusion, our data demonstrated that elevated Ajuba expression is correlated with poor BC prognosis and regulated malignant behavior through TAZ-GLUT3/Survivin signaling in BC cells.
    Journal
    |
    BIRC5 (Baculoviral IAP repeat containing 5) • AJUBA (Ajuba LIM Protein)
    |
    BIRC5 expression • AJUBA overexpression
    |
    paclitaxel